Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
By M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, J. Bousquet, K. Beeh, S. Ramos, G. W. Canonica, S. Hedgecock and 3 more. Allergy. European Journal of Allergy and Clinical Immunology, 2005
1,171 citations recorded by the source corpus.
Background: Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult‐to‐treat patient population.
Subfields: Dermatology, Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/9453403625b88fd4bc5cf3ab0914d784c02a19ea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Physiology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. (2009, neutral): “86/patient/year) in more severe asthma (371).”
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (2013, methodology): “We reviewed all original publications from those reviews and additional RCTs we identified [268-283].”
- A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy (2013, background): “In patients with severe asthma, for example, use of the anti-immunoglobulin E (IgE) monoclonal antibody, omalizumab, has been shown to reduce the occurrence of asthma exacerbations requiring systemic corticosteroid therapy and to improve symptoms and asthma-related quality of life [127].”